{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:43:36Z","timestamp":1794645816171,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.xcrm.2024.101580","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:07:26Z","timestamp":1716289646000},"page":"101580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia"],"prefix":"10.1016","volume":"5","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changcheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-8856","authenticated-orcid":false,"given":"Fang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101580_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101580_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","article-title":"Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders","volume":"21","author":"Maskalenko","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101580_bib3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2024.101580_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101580_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101580_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2024.101580_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2024.101580_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101580_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T\u00a0cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101580_bib10","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101580_bib11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101580_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101580_bib13","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101580_bib14","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101580_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2024.101580_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683381","article-title":"Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment","volume":"12","author":"Kaweme","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101580_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2024.101580_bib18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","article-title":"Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101580_bib19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101580_bib20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41590-023-01462-9","article-title":"Tumors evade immune cytotoxicity by altering the surface topology of NK cells","volume":"24","author":"Zheng","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101580_bib21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.ymthe.2017.06.003","article-title":"Quantitative Imaging Approaches to Study the CAR Immunological Synapse","volume":"25","author":"Mukherjee","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101580_bib22","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202002145","article-title":"The septin cytoskeleton regulates natural killer cell lytic granule release","volume":"219","author":"Phatarpekar","year":"2020","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101580_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101580_bib24","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1038\/s41467-019-11947-7","article-title":"Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome","volume":"10","author":"Yang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101580_bib25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The Broad Spectrum of Human Natural Killer Cell Diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101580_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101580_bib27","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive Integration of Single-Cell Data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101580_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: Biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2024.101580_bib29","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/MCB.20.8.2687-2695.2000","article-title":"The Rel\/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L)","volume":"20","author":"Chen","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101580_bib30","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1002\/jcp.26487","article-title":"Regulation of RhoA GTPase and various transcription factors in the RhoA pathway","volume":"233","author":"Kim","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.xcrm.2024.101580_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.imlet.2008.10.008","article-title":"Re-organization of mitochondria at the NK cell immune synapse","volume":"122","author":"Abarca-Rojano","year":"2009","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.xcrm.2024.101580_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101580_bib33","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","article-title":"A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing","volume":"6","author":"Lizotte","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2024.101580_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11154","article-title":"Repression of GSK3 restores NK cell cytotoxicity in AML patients","volume":"7","author":"Parameswaran","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101580_bib35","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","article-title":"Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101580_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108497","article-title":"Venetoclax enhances NK cell killing sensitivity of\u00a0AML cells through the NKG2D\/NKG2DL activation pathway","volume":"104","author":"Wu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2024.101580_bib37","article-title":"Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice","volume":"4","author":"Arandjelovic","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2024.101580_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01730-22","article-title":"The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin\/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model","volume":"96","author":"Chandrasekar","year":"2022","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101580_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001151","article-title":"Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse","volume":"9","author":"Rak","year":"2011","journal-title":"PLoS Biol."},{"key":"10.1016\/j.xcrm.2024.101580_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188860","article-title":"The mechanobiology of NK cells- 'Forcing NK to Sense' target cells","volume":"1878","author":"Wong","year":"2023","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101580_bib41","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/1535-7163.MCT-19-1109","article-title":"Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response","volume":"20","author":"Greenman","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2024.101580_bib42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101580_bib43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41587-022-01650-2","article-title":"Synapse-tuned CARs enhance immune cell anti-tumor activity","volume":"41","author":"Chockley","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101580_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing Cancer Immunotherapies That Engage T Cells and NK Cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101580_bib45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13287-021-02377-8","article-title":"Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy","volume":"12","author":"Choi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.xcrm.2024.101580_bib46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.04.005","article-title":"Metabolic pathways in immune cell activation and quiescence","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101580_bib47","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2022008221","article-title":"Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells","volume":"7","author":"Teh","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101580_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101580_bib49","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1158\/0008-5472.CAN-19-3578","article-title":"The Fire Within: NF-\u03baB Involvement in Non-Small Cell Lung Cancer","volume":"80","author":"Dimitrakopoulos","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101580_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101580_bib51","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","article-title":"Emerging therapies in cancer metabolism","volume":"35","author":"Xiao","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2024.101580_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2024.101580_bib53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","article-title":"Untimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells","volume":"600","author":"Witkowski","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101580_bib54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101580_bib55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13073-022-01049-3","article-title":"Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19","volume":"14","author":"Guo","year":"2022","journal-title":"Genome Med."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:15:09Z","timestamp":1718709309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124002726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666379124002726"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101580","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101580"}}